Nipro is recalling glucose meters over a display mixup

Nipro Diagnostics is recalling certain models of its TrueBalance glucose meter.--Courtesy of Nipro

Japanese giant Nipro Diagnostics is pulling some of its glucose meters off the shelf over a unit-of-measure error that could lead customers to misread them and misunderstand blood sugar levels.

About 500 total TrueBalance and TrueTrack meters are affected, Nipro said, as a factory error left the devices displaying blood glucose in millimoles per liter, not the more common milligrams per deciliter. If a user doesn't notice the difference, he or she might believe glucose levels are much lower than they are, the company said.

Nipro is now asking customers with affected to devices to return them for a replacement. The company said it hasn't heard of any adverse events tied to the display issue. The FDA is aware of the voluntary recall, according to Nipro, but the agency is yet to weigh in on the effort.

The recall is unlikely to have a meaningful effect on earnings for the well-diversified company. Nipro hauled in $1.4 billion in sales in the 6 months that ended Sept. 30, and the company's medical device segment accounted for $1.1 billion of that. In addition to its fleet of diabetes and dialysis devices, Nipro makes money off of Japanese commercial rights to stateside inventions including Thoratec's ($THOR) HeartMate II and Infraredx's TVC imaging system.

- read the statement

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.